10/13/2025
🧠 A brain tumor nearly vanished in just 5 days after one dose of a breakthrough treatment.
Experts say this may be the beginning of a cure.
In a landmark clinical trial at Massachusetts General Cancer Center, researchers have reported rapid and dramatic responses to a next-generation CAR-T cell therapy in patients with glioblastoma—one of the deadliest and most treatment-resistant brain cancers.
The personalized treatment reprograms a patient’s immune cells to attack the tumor, and in one extraordinary case, nearly eliminated the cancer within just five days. This novel therapy is designed to target multiple features of the tumor at once, a strategy that may help overcome the common challenge of treatment resistance in solid tumors like glioblastoma.
Although the tumors eventually returned, the early outcomes were described as unprecedented. One patient saw a 60% reduction in tumor size that lasted for half a year—an impressive result in a cancer known for its aggressiveness.
The trial’s success marks a major step forward for immunotherapy in brain cancer and raises new hopes for long-term control or even a cure. Researchers are now working to refine the treatment and extend its effects, with the ultimate goal of turning a once-terminal diagnosis into a survivable condition.
source
Source: Mass General Cancer Center. “A Major Milestone in Glioblastoma Research.”
